📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
40 announcements match the current filters (relevance ≥ 5).
Anupam Rasayan to Acquire 43.3% Stake in Bliss GVS Pharma for ₹1,369.5 Cr at ₹299/Share
Anupam Rasayan India Limited has entered into a Share Purchase Agreement (SPA) to acquire a 43.30% stake in Bliss GVS Pharma from its promoters and select public shareholders. The transaction is priced at ₹299 per share, representing a total consideration of approximately ₹1,369.51 crore. This acquisition triggers a mandatory open offer for an additional 26% stake from public shareholders. Upon completion, Anupam Rasayan will assume management control and be reclassified as the promoter of the company.
Key Highlights
Anupam Rasayan to acquire 4,58,03,024 shares (43.30% stake) at a fixed price of ₹299 per share.
Total deal value for the initial 43.30% stake is calculated at ₹1,369.51 crore.
Mandatory open offer triggered for up to 26% of the total paid-up equity capital at the same price or as per SEBI norms.
Purchaser holds a call option to acquire an additional 4.90% stake (Option Shares) at a floor price of ₹299.
The transaction will result in a complete change of control and promoter classification for Bliss GVS Pharma.
👀 What to Watch
Investors should note the acquisition price of ₹299 as a significant valuation benchmark and monitor the upcoming open offer details. The entry of a strategic corporate promoter like Anupam Rasayan may improve long-term governance and operational synergies.
Anupam Rasayan to Acquire Control of Bliss GVS Pharma; Open Offer at ₹299 per Share
Anupam Rasayan India Limited has entered into a Share Purchase Agreement to acquire a 43.30% stake in Bliss GVS Pharma from its promoters and other shareholders. This acquisition has triggered a mandatory open offer to public shareholders for an additional 26% stake (2,77,26,848 shares) at a price of ₹299 per share. The total cash consideration for the open offer is estimated at ₹829.03 crore, assuming full acceptance. This transaction marks a significant change in the management and control of Bliss GVS Pharma.
Key Highlights
Acquisition of 4,58,03,024 shares (43.30% stake) via SPA at a price of ₹299 per share.
Mandatory Open Offer for 2,77,26,848 shares (26% of expanded capital) at ₹299 per share.
Total open offer value is ₹829.03 crore to be paid entirely in cash.
The deal triggers a change in control from existing promoters to Anupam Rasayan India Limited.
👀 What to Watch
Investors should evaluate the offer price of ₹299 against the current market price to determine the benefit of tendering shares. Long-term investors may monitor how the change in control to Anupam Rasayan impacts the company's strategic direction.
Bliss GVS Pharma Recommends 100% Dividend and Reports Audited FY26 Financial Results
Bliss GVS Pharma has approved its audited standalone and consolidated financial results for the fiscal year ending March 31, 2026. A significant highlight for shareholders is the recommendation of a 100% final dividend, which translates to ₹1 per equity share. The company also confirmed the expansion of its global operations through new subsidiaries in Kenya and the Democratic Republic of the Congo. Shareholders will vote on these proposals at the upcoming Annual General Meeting scheduled for July 15, 2026.
Key Highlights
Recommended a final dividend of 100%, equivalent to ₹1 per equity share of face value ₹1.
Approved audited financial results for the full year ended March 31, 2026, with an unmodified audit opinion.
Expanded global footprint with new subsidiaries: Theralife Pharma Ltd (Kenya) and Theralife Pharma RDC (Congo).
Re-appointed BDO India Services Private Limited as the Internal Auditor for the 2026-27 financial year.
Scheduled the 41st Annual General Meeting for July 15, 2026, to be held via video conferencing.
👀 What to Watch
The 100% dividend payout reflects management's confidence in the company's cash position and profitability. Investors should review the consolidated performance to gauge the impact of the new African subsidiaries on overall margins.
Bliss GVS Pharma Recommends 100% Dividend and Approves FY26 Audited Results
Bliss GVS Pharma has recommended a final dividend of 100%, amounting to ₹1 per equity share for the financial year ended March 31, 2026. The Board approved the audited standalone and consolidated financial results with an unmodified audit opinion, indicating healthy reporting standards. The company also confirmed the re-appointment of BDO India Services as Internal Auditors and highlighted recent expansions into Kenya and the Democratic Republic of the Congo. The 41st Annual General Meeting is scheduled for July 15, 2026.
Key Highlights
Recommended a final dividend of 100% (₹1 per share) on a face value of ₹1 for FY 2025-26.
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Re-appointed M/s. BDO India Services Private Limited as Internal Auditor for the financial year 2026-27.
Expanded global operations with new subsidiaries in Kenya (Nov 2025) and DR Congo (Jan 2026).
Scheduled the 41st Annual General Meeting (AGM) for July 15, 2026, via video conferencing.
👀 What to Watch
Investors should consider the 100% dividend payout as a positive sign of cash flow and monitor the performance of new African subsidiaries for long-term growth. The unmodified audit opinion provides confidence in the company's financial disclosures.
Bliss GVS Pharma Recommends 100% Final Dividend and Reports FY26 Results
Bliss GVS Pharma's Board has recommended a final dividend of Rs. 1 per share, representing 100% of the face value for the financial year ended March 31, 2026. The company reported its audited standalone and consolidated financial results for FY26 with an unmodified audit opinion from its auditors. During the fiscal year, the company expanded its international presence by incorporating new subsidiaries in Kenya and the Democratic Republic of the Congo. The 41st Annual General Meeting is scheduled for July 15, 2026, to seek shareholder approval for the dividend and other matters.
Key Highlights
Recommended a final dividend of 100%, equivalent to Rs. 1 per equity share on a face value of Rs. 1 each.
Auditors issued an unmodified opinion on the annual audited standalone and consolidated financial results for FY 2025-26.
Expanded global operations with new subsidiaries: Theralife Pharma Ltd (Kenya) and Theralife Pharma RDC (Congo).
Re-appointed BDO India Services Private Limited as the Internal Auditor for the financial year 2026-27.
The 41st Annual General Meeting (AGM) is scheduled to be held on July 15, 2026, via video conferencing.
👀 What to Watch
Investors should track the upcoming record date for the Rs. 1 dividend and monitor the revenue contribution from the newly established African subsidiaries in future quarters.
Bliss GVS Pharma Recommends 100% Final Dividend of Rs 1 per Share for FY 2025-26
Bliss GVS Pharma has approved its audited financial results for the fiscal year ended March 31, 2026, and recommended a final dividend of Rs 1 per share (100% of face value). The company's auditors provided an unmodified opinion on both standalone and consolidated financial statements, indicating no major accounting discrepancies. Additionally, BDO India Services has been re-appointed as the internal auditor for the upcoming fiscal year. The Annual General Meeting is scheduled for July 15, 2026, to finalize these approvals.
Key Highlights
Recommended a final dividend of 100%, which is Rs 1 per equity share of face value Rs 1.
Audited standalone and consolidated financial results for FY 2025-26 approved with an unmodified audit opinion.
Re-appointment of M/s. BDO India Services Private Limited as Internal Auditor for FY 2026-27.
41st Annual General Meeting scheduled for July 15, 2026, via video conferencing.
Consolidated results now include new subsidiaries in Kenya and the Democratic Republic of the Congo.
👀 What to Watch
Investors should track the record date for the Rs 1 dividend payout and review the full earnings report to assess the growth of the new African subsidiaries. The 100% dividend recommendation reflects management's confidence in the company's cash flow.
Bliss GVS Pharma Assigned [ICRA]A- (Stable) Rating for Rs 100 Crore Bank Facilities
ICRA Limited has assigned new credit ratings to Bliss GVS Pharma Limited for its bank facilities totaling Rs 100.00 crore. The long-term rating is established at [ICRA]A- with a Stable outlook, while the short-term rating is assigned as [ICRA]A2+. These ratings apply to fund-based and non-fund-based limits specifically associated with Federal Bank. This independent assessment reflects the company's creditworthiness and provides a benchmark for its financial stability.
Key Highlights
Assigned [ICRA]A- (Stable) long-term rating for Rs 100.00 crore bank facilities
Assigned [ICRA]A2+ short-term rating for fund-based and non-fund-based limits
The rating action covers facilities specifically held with Federal Bank Limited
The 'Stable' outlook indicates ICRA's expectation of a steady credit profile in the medium term
👀 What to Watch
Investors should view this as a positive validation of the company's financial health and debt-servicing capability. This investment-grade rating provides a baseline for monitoring the company's future financial risk and borrowing costs.
Bliss GVS Pharma Appoints Two Independent Directors with 35+ Years Experience
Bliss GVS Pharma has appointed Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Additional Independent Directors for a five-year term starting April 3, 2026. Mr. Mahadevan brings over 35 years of global finance leadership from major pharmaceutical firms such as Novartis and Sandoz. Mr. Shah is a veteran Chartered Accountant with over 36 years of experience in taxation and audit, currently serving on boards like Siyaram Silk Mills. These appointments are intended to strengthen the board's strategic oversight and financial governance, subject to shareholder approval via postal ballot.
Key Highlights
Appointment of two Independent Directors for a 5-year term from April 3, 2026, to April 2, 2031
Mr. Vijayanarayanan Mahadevan brings 35+ years of experience in global finance and pharma manufacturing
Mr. Deepak Rameshchandra Shah brings 36+ years of expertise in taxation, audit, and corporate leadership
Board has approved the draft Postal Ballot Notice to seek shareholder approval for these appointments
👀 What to Watch
Investors should view these appointments as a positive move to enhance board-level expertise and corporate governance. No immediate action is required as these are routine but high-quality leadership additions.
Bliss GVS Pharma Appoints Two Independent Directors for 5-Year Terms
Bliss GVS Pharma has approved the appointment of Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Additional Independent Directors for five-year terms effective April 03, 2026. Mr. Mahadevan brings over 35 years of finance leadership experience from global firms like Novartis and Sandoz, while Mr. Shah has over 36 years of expertise in taxation and audit. The company is seeking shareholder approval for these appointments via a postal ballot. These additions are expected to strengthen the board's strategic financial oversight and corporate governance.
Key Highlights
Appointment of Mr. Vijayanarayanan Mahadevan as Independent Director for a 5-year term until April 2031.
Appointment of Mr. Deepak Rameshchandra Shah as Independent Director for a 5-year term until April 2031.
Mr. Mahadevan has 35+ years of experience in finance functions across manufacturing and R&D sectors.
Mr. Shah has 36+ years of experience in taxation and serves on boards of companies like Siyaram Silk Mills.
The board has approved a Postal Ballot Notice to seek member approval for these appointments.
👀 What to Watch
Investors should view the addition of seasoned finance and taxation professionals to the board as a positive move for corporate governance. No immediate action is required as these are routine but high-quality board reinforcements.
Bliss GVS Pharma Announces TDS Guidelines for Re. 0.50 Interim Dividend; Record Date Feb 18
Bliss GVS Pharma has declared an interim dividend of Re. 0.50 per equity share for the financial year 2025-2026. The company has established February 18, 2026, as the record date to identify eligible shareholders for this payout. This communication outlines the Tax Deduction at Source (TDS) procedures, where a 10% tax will be deducted for resident shareholders with a valid PAN. Shareholders must submit necessary tax exemption forms like 15G/15H by February 23, 2026, to avoid higher tax withholding.
Key Highlights
Interim dividend of Re. 0.50 per equity share (50% of face value) declared for FY 2025-26.
Record date for dividend eligibility is fixed as Wednesday, February 18, 2026.
TDS of 10% applies to resident shareholders with PAN; 20% applies if PAN is invalid or not linked to Aadhaar.
No TDS for resident individuals if the total dividend received during FY 2025-26 does not exceed Rs. 10,000.
Deadline for submitting tax-related documents (Form 15G/15H/TRC) is Monday, February 23, 2026.
👀 What to Watch
Shareholders should ensure their PAN and Aadhaar are linked and bank details are updated in their demat accounts to receive the dividend smoothly. If eligible for tax exemption, submit Form 15G/15H to the company's registrar by the February 23 deadline.
Bliss GVS Pharma Clarifies Speculative News Regarding Stake Sale to Anupam Rasayan
Bliss GVS Pharma has officially addressed a news report from CNBC Awaaz dated February 13, 2026, which suggested that Anupam Rasayan might acquire a stake in the company. The company clarified that this news is speculative and did not originate from any official communication. As of the current date, no arrangement or decision regarding a stake sale has been finalized or approved by the promoters. The disclosure was made under Regulation 30(11) to prevent the establishment of false market sentiment.
Key Highlights
Company denies CNBC Awaaz report titled 'Bliss GVS में हिस्सा ले सकती है अनुपम रसायन' as speculative.
Management confirms no decision or arrangement has been crystallized or approved by promoters as of Feb 13, 2026.
Clarification issued under SEBI Regulation 30(11) to maintain market integrity.
Investors advised to rely only on official exchange filings rather than media reports.
👀 What to Watch
Investors should remain cautious and avoid reacting to unverified media reports, as the company has officially denied any finalized deal. Monitor the stock for volatility but prioritize official regulatory filings for investment decisions.
Bliss GVS Pharma: Two Whole-Time Directors Resign Effective February 10, 2026
Bliss GVS Pharma Limited has announced the resignation of two Whole-Time Directors, Mrs. Shruti Vishal Rao and Dr. Vibha Gagan Sharma, effective February 10, 2026. Both directors are daughters of the current Managing Director and CEO, Mr. Narsimha Shibroor Kamath, and cited other professional commitments as the reason for their departure. The Board accepted these resignations in a meeting held at shorter notice on the same day. This simultaneous exit of two family-member directors from the board marks a significant change in the company's executive leadership structure.
Key Highlights
Resignation of Mrs. Shruti Vishal Rao and Dr. Vibha Gagan Sharma as Whole-Time Directors effective Feb 10, 2026.
Both outgoing directors are daughters of the Managing Director & CEO, Mr. Narsimha Shibroor Kamath.
The resignations were attributed to other professional commitments by the directors.
The Board meeting to accept the resignations was held at shorter notice on February 10, 2026, between 5:30 PM and 6:00 PM.
Both individuals will also cease to be members of all company committees effective immediately.
👀 What to Watch
Investors should monitor for any new board appointments to understand if the company is moving towards more professional management or if other family members will be inducted. The simultaneous exit of two promoter-related directors warrants a watch on the company's future succession and governance strategy.
Bliss GVS Pharma Declares 50% Interim Dividend; Sets Feb 18 as Record Date
Bliss GVS Pharma Limited has announced an interim dividend of ₹0.50 per equity share for the financial year 2025-2026. This payout represents 50% of the face value of ₹1 per share. The company has officially fixed Wednesday, February 18, 2026, as the record date to determine shareholder eligibility. The dividend is expected to be disbursed to eligible shareholders within 30 days of its declaration on February 10, 2026.
Key Highlights
Interim dividend of ₹0.50 per equity share (50% of face value ₹1) declared
Record date for dividend eligibility fixed as February 18, 2026
Dividend declared for the Financial Year 2025-2026
Payment to be completed within 30 days from the declaration date of February 10, 2026
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date to be eligible for the ₹0.50 per share payout. This announcement reflects a positive cash return to shareholders for the current fiscal year.
Bliss GVS Pharma Declares Interim Dividend of Rs 0.50 Per Share; Sets Record Date
Bliss GVS Pharma has declared an interim dividend of Rs 0.50 per equity share for the financial year 2025-26, which represents 50% of the face value of Re 1. The company has fixed February 18, 2026, as the record date to determine shareholder eligibility for this payout. This announcement was made alongside the approval of the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The dividend is scheduled to be paid to eligible shareholders within 30 days of its declaration.
Key Highlights
Interim dividend declared at Rs 0.50 per equity share (50% of face value)
Record date for dividend eligibility fixed as February 18, 2026
Dividend payment to be completed within 30 days from February 10, 2026
Approved unaudited standalone and consolidated financial results for Q3 FY26
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the record date of February 18, 2026. Additionally, shareholders should review the Q3 financial results to assess the company's operational performance.
Bliss GVS Pharma Approves Q3 FY26 Results; Declares 50% Interim Dividend
Bliss GVS Pharma Limited has approved its standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. In a positive move for shareholders, the Board declared an interim dividend of 50%, amounting to ₹0.50 per equity share on a face value of ₹1. The company has fixed February 18, 2026, as the record date for dividend eligibility. The dividend is scheduled to be paid within 30 days of the declaration.
Key Highlights
Approved unaudited standalone and consolidated financial results for Q3 and 9M FY2025-26.
Declared an interim dividend of 50%, which is ₹0.50 per equity share of face value ₹1.
Fixed Wednesday, February 18, 2026, as the record date for determining eligible shareholders.
Committed to paying the interim dividend within 30 days from the date of declaration.
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the record date of February 18, 2026. A detailed review of the full financial results is recommended to assess the company's underlying growth and margin performance.
Bliss GVS Pharma Declares ₹0.50 Interim Dividend; Sets Feb 18 as Record Date
Bliss GVS Pharma has declared an interim dividend of ₹0.50 per equity share for the financial year 2025-2026, representing a 50% payout on the face value of ₹1. The Board has fixed February 18, 2026, as the record date to determine eligible shareholders for this payment. This announcement was made alongside the approval of the company's unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The dividend is mandated to be paid within 30 days of its declaration.
Key Highlights
Interim dividend of ₹0.50 per equity share declared (50% of face value).
Record date for dividend eligibility set for February 18, 2026.
Dividend payment to be completed within 30 days from February 10, 2026.
Board approved unaudited financial results for Q3 and 9M ended December 31, 2025.
👀 What to Watch
Investors looking to benefit from the dividend should ensure they hold the stock before the record date of February 18, 2026. Additionally, shareholders should review the Q3 financial results to evaluate the company's underlying earnings strength.
Bliss GVS Shareholders Approve Narsimha Kamath as Managing Director with 99.9% Majority
Bliss GVS Pharma Limited has announced the successful passage of a special resolution to appoint Mr. Narsimha Shibroor Kamath as Managing Director. The resolution was passed via postal ballot with an overwhelming majority of 99.90% of the votes cast in favour. A total of 6.37 crore votes were polled, representing approximately 60.21% of the total shareholding. The promoter group and public institutions showed unanimous support for the appointment, indicating strong internal and institutional alignment.
Key Highlights
Special resolution passed for the appointment of Mr. Narsimha Shibroor Kamath as Managing Director
Total votes polled reached 6,36,93,053, representing 60.21% of the total 10.58 crore shares
The appointment received 99.90% approval (6,36,26,720 votes) from participating shareholders
Promoter group and Public Institutions voted 100% in favour of the resolution
Only 0.10% of votes (66,333) were cast against the proposal
👀 What to Watch
Investors should view this as a positive sign of leadership continuity and strong shareholder backing. No immediate action is required, but monitoring the new MD's strategic direction for the company is advised.
Bliss GVS Pharma Proposes Appointment of Narsimha Shibroor Kamath as Managing Director
Bliss GVS Pharma has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Narsimha Shibroor Kamath as Managing Director for a three-year term. Mr. Kamath, who currently serves as the Chief Executive Officer, will be redesignated as Managing Director & CEO upon approval. As he is 72 years old, the company is seeking a special resolution to confirm that his continued leadership is in the best interest of the firm. The e-voting process for shareholders will run from December 31, 2025, to January 29, 2026.
Key Highlights
Proposed appointment of current CEO Mr. Narsimha Shibroor Kamath as Managing Director for a 3-year tenure.
Special resolution required due to the appointee's age of 72 years as per Companies Act requirements.
E-voting period scheduled from December 31, 2025, to January 29, 2026, with results by February 2, 2026.
The appointee will hold the dual designation of Managing Director & Chief Executive Officer.
The board has appointed Mr. Vijay Yadav of AVS & Associates as the scrutinizer for the voting process.
👀 What to Watch
Investors should monitor the voting results to ensure leadership continuity and review the detailed explanatory statement for specifics on the proposed remuneration package.
Bliss GVS Pharma Appoints Promoter S.N. Kamath as MD & CEO for 3-Year Term
The Board of Bliss GVS Pharma has approved the appointment of Mr. S. N. Kamath as Managing Director and CEO for a three-year term, subject to shareholder approval. Mr. Kamath, who is currently the CEO and a promoter, has been instrumental in expanding the company's global footprint to over 60 countries. The transition formalizes his leadership role as the company seeks to maintain its strategic growth trajectory. The appointment will be finalized following a Special Resolution passed via Postal Ballot.
Key Highlights
Appointment of Mr. S. N. Kamath as Managing Director for a 3-year consecutive term.
Mr. Kamath is the company promoter and has been serving as the Chief Executive Officer.
Under his leadership, the company has established a presence in more than 60 countries.
The appointment is subject to shareholder approval through a Special Resolution via Postal Ballot.
Mr. Kamath is the father of two existing Whole-Time Directors, ensuring family-led management continuity.
👀 What to Watch
This move signals leadership stability and continued promoter commitment to the company's operations. Investors should monitor the Postal Ballot results and look for any new strategic initiatives under his formal MD tenure.
Bliss GVS Pharma Appoints CEO S.N. Kamath as Managing Director for 3-Year Term
The Board of Bliss GVS Pharma has approved the appointment of current CEO and promoter Mr. S.N. Kamath as the Managing Director for a period of three years. This appointment is subject to shareholder approval via a Special Resolution through a Postal Ballot. Mr. Kamath, who has been instrumental in expanding the company's presence to over 60 countries, will hold the dual title of MD & CEO. As a promoter and father to two existing Whole-Time Directors, this move ensures leadership continuity within the founding family.
Key Highlights
Mr. S.N. Kamath appointed as Managing Director for a 3-year consecutive term.
Transition from CEO to MD & CEO role pending shareholder approval via Postal Ballot.
Mr. Kamath is the company promoter and has led expansion into 60+ international markets.
Board meeting conducted on December 23, 2025, from 11:47 A.M. to 13:45 P.M.
Mr. Kamath is related to two other Whole-Time Directors, Dr. Vibha Gagan Sharma and Mrs. Shruti Vishal Rao.
👀 What to Watch
Investors should see this as a move for leadership stability and continuity. No immediate action is required, but shareholders should participate in the upcoming Postal Ballot regarding the Special Resolution.
